Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03505996
Recruitment Status : Active, not recruiting
First Posted : April 23, 2018
Last Update Posted : February 17, 2022
Information provided by (Responsible Party):
CStone Pharmaceuticals

Brief Summary:
This is a multicenter, single-arm phase II study to evaluate the efficacy and safety of CS1001 monotherapy for relapsed/refractory classical Hodgkin Lymphoma (rr-cHL)

Condition or disease Intervention/treatment Phase
Hodgkin Lymphoma Biological: CS1001 Phase 2

Detailed Description:
Eligible subjects with rr-cHL who failed at least two prior lines of therapies are planned to receive CS1001 1200 mg intravenous infusion every three weeks until progression of disease, intolerable toxicity, consent withdrawn or death.The primary endpoint of this trial is objective response rate (ORR), as assessed by independent radiological review committee (IRRC) based on Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Actual Study Start Date : June 1, 2018
Actual Primary Completion Date : February 19, 2020
Estimated Study Completion Date : March 31, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CS1001
Participants will receive CS1001 1200 mg by intravenous infusion every three weeks
Biological: CS1001
Monoclonal antibody

Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: From first patient first visit to 6 month after last patient first visit ]
    The percentage of subjects whose best overall response is either complete response or partial response evaluated by IRRC according to Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects with histologically confirmed cHL at study site.
  2. Relapsed or refractory cHL that failed at least two lines of systemic therapy.
  3. ECOG PS of 0-2.
  4. Subjects with at least one measurable lesion at baseline.
  5. Subjects treated by prior anti-cancer therapy whose toxicity resolved to baseline or =< Grade 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03
  6. Subjects who agree to use highly effective contraception.

Exclusion Criteria:

  1. Nodular lymphocyte predominant Hodgkin lymphoma or grey zone lymphoma.
  2. Primary site in central nervous system (CNS) or CNS involvement.
  3. Subjects currently participating in other clinical studies or use of any investigational drug within 4 weeks prior to the first dose of CS1001.
  4. Subjects who had systemic corticosteroid or any other immunosuppressive therapy within 14 days prior to the first dose of CS1001.
  5. Subject who had chemotherapy, immune therapy or biological therapy as systemic anti-cancer treatment within 28 days prior to the first dose of CS1001.
  6. Receipt of traditional medicinal herbal preparations within 7 days prior to the first dose of CS1001.
  7. Known history of human immunodefiency virus (HIV) infection and/or acquired immune deficiency syndrome.
  8. Subjects with active Hepatitis B or C infection.
  9. Subjects with active tuberculosis infection.
  10. Subjects who received prior therapy with anti-PD-1, anti-PD-L1 or anti CTLA-4 monoclonal antibody.
  11. Female subjects who are pregnant or breast-feeding.

For more information regarding trial participation, please contact at

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03505996

Layout table for location information
Beijing Cancer Hospital
Beijing, China
Sponsors and Collaborators
CStone Pharmaceuticals
Layout table for additonal information
Responsible Party: CStone Pharmaceuticals Identifier: NCT03505996    
Other Study ID Numbers: CS1001-202
CTR20180423 ( Registry Identifier: )
First Posted: April 23, 2018    Key Record Dates
Last Update Posted: February 17, 2022
Last Verified: February 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases